Pharming secures novel EU approval for Joenja in activated PI3K delta syndrome

CE2026-05-26T10:56:00

Source:

European approval provides a targeted approach that addresses the underlying pathophysiology of activated PI3K delta syndrome (APDS).

The European Commission (EC) has authorised Joenja (leniolisib) as the first treatment for activated PI3K delta syndrome (APDS) in the EU, following first characterisation of the disease in 2013.

Pharming Group’s oral small molecule phosphoinositide 3-kinase (PI3K) delta inhibitor, is indicated for patients

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member